蔚蓝生物(603739.SH):5-8月累计收到政府补助852.27万元
格隆汇8月31日丨蔚蓝生物(603739.SH)公布,自2019年5月至2019年8月,公司及公司全资子公司青岛康地恩动物药业有限公司、青岛蔚蓝生物集团有限公司、山东康地恩生物科技有限公司、潍坊康地恩生物科技有限公司、潍坊康地恩生物科技有限公司青岛分公司,控股子公司上海康地恩生物科技有限公司、青岛动保国家工程技术研究中心有限公司、潍坊诺达药业有限公司累计收到与收益相关的政府补助合计人民币852.27万元,占公司最近一个会计年度经审计净利润的10.22%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.